MAML2
Overview
MAML2 (Mastermind Like Transcriptional Coactivator 2) is a transcriptional co-activator in the NOTCH signalling pathway, forming a ternary complex with NOTCH intracellular domain and CSL transcription factors. In pancreatic ductal adenocarcinoma (PAAD), MAML2 is part of recurrent NOTCH-pathway alterations that collectively affect 31% of cases and nominate γ-secretase inhibitors as candidate therapies.
Alterations observed in the corpus
- MAML2 part of NOTCH-pathway alterations (NOTCH1–4, JAG1/JAG2, MAML1–3) totalling 31% of cases in a 109-case PDA WES cohort; amplification/mutation patterns nominate γ-secretase inhibitor MK0752 as a candidate therapy. PMID:25855536
Cancer types (linked)
- PAAD: Part of the NOTCH-pathway alteration cluster in a 109-case whole-exome sequencing cohort of resected pancreatic ductal adenocarcinoma. PMID:25855536
Co-occurrence and mutual exclusivity
- Co-altered with NOTCH1–4, JAG1, JAG2, and MAML1/MAML3 as part of the broader NOTCH-pathway alteration cluster in PDA. PMID:25855536
Therapeutic relevance
- NOTCH-pathway alterations including MAML2 in 31% of PDA cases nominate γ-secretase inhibitor MK0752 as a candidate therapy. PMID:25855536
Open questions
- Specific alteration types (amplification vs. mutation) and frequencies of individual MAML family members in PDA are not broken out per gene. PMID:25855536
Sources
This page was processed by crosslinker on 2026-05-14.